65176-93-4

Usage

Chemical Properties

White to Off-White Solid

Uses

Intermediate in the preparation of Histamine antagonists and Omeprazole metabolites

Upstream product

• 72716-80-4 2-hydroxy-5,6-dimethylnicotinonitrile 
• 78-93-3 butanone 
• 107-91-5 cyanoacetic acid amide 
• 109-94-4 formic acid ethyl ester 
• 72716-80-4 1,2-dihydro-5,6-dimethyl-2-oxo-3-pyridinecarbonitrile 

Downstream Products

• 82756-25-0 5,6-dimethyl-2-anilinonicotinonitrile 
• 113124-09-7 5,6-dimethyl-3-pyridinecarbonitrile 
• 65176-92-3 2-chloro-5,6-dimethylnicotinaldehyde 
• 90713-68-1 2-Anilino-5,6-dimethylnicotinic acid 
• 82756-26-1 5,6-dimethyl-2-anilinonicotinamide 

Relevant academic research and scientific papers

Synthesis, Neurotropic Activity, and Molecular Docking of New Condensed Thieno[2,3-b]pyridine Derivatives

Abstract: Methods for the preparation of new condensed derivatives of pyrido[3',2':4,5]thieno[3,2-d]pyrimidines based on 5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonitrile were developed. Substitution reactions in the 3rd and 4th positions of 7,8-dimethylpyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4(3H)-one were conducted. The neurotropic activity of 12 obtained compounds was studied in vivo in rats and mice. Eight compounds were found to have an anticonvulsant effect of antagonism with corazole. Four selected compounds had anxiolytic and behavior activating effects. Molecular docking of the synthesized compounds was performed to predict their interaction with the GABAA receptor. Five compounds were identified, the complexation of which with the GABAA receptor occurs in two places: the benzamidine site of subsite 1 and subsite 3 of the ECD interface, which indicates the inhibitory effect of the compounds on the target.

CHEMICAL COMPOUNDS

Compounds of Formula (I), specifically hepatitis B virus and/or hepatitis D virus inhibitors, more specifically compounds that inhibit HBe antigen and HBs antigen in a subject, for the treatment of viral infections, and methods of preparing and using such compounds.

HETEROCYCLIC COMPOUND

The present invention provides a compound having an ACC inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention provides a compound represented by the formula (I): wherein each symbol is as in the specification, or a salt thereof.

SPIRO-RING COMPOUND

The present invention aims to provide a compound having an acetyl-CoA carboxylase (ACC) inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention provides a compound represented by the formula (I): wherein R1 is a hydrogen atom or a substituent; ring P is an optionally substituted 6-membered nitrogen-containing aromatic heterocycle; ring Q is an optionally further substituted 5- to 7-membered nitrogen-containing non-aromatic heterocycle; and ring R is an optionally fused 5- to 7-membered non-aromatic ring, which is further optionally substituted, or a salt thereof.

NOVEL BENZYLAMINE DERIVATIVES AS CETP INHIBITORS

The present invention provides, among other things, new benzylamine compounds, compositions comprising benzylamine compounds, methods of making benzylamine compounds, and methods of using benzylamine compounds for treating or preventing a variety of conditions or diseases associated with lipoprotein metabolism.

Pyrimidine compounds

The compounds are substituted pyrimidine compounds which are histamine H2 -antagonists. A specific compound of the present invention is 2-[2-(5-dimethylaminomethyl)-2-furylmethylthio)ethylamino]-5-(3-pyridylmethyl)-4-pyrimidone.